Background: In the first 5 years after their stroke, about a quarter of patients will suffer from a recurrent stroke. Digital health interventions facilitating interactions between a caregiver and a patient from a distance are a promising approach to improve patient adherence to lifestyle changes proposed by secondary prevention guidelines. Many of these interventions are not implemented in daily practice, even though efficacy has been shown. One of the reasons can be the lack of clear economic incentives for implementation. We propose to map all health economic evidence regarding digital health interventions for secondary stroke prevention. Summary: We performed a systematic search according to PRISMA-P guidelines and searched on PubMed, There is a lack of evidence on health economic outcomes on digital health interventions for secondary stroke prevention. Future research in this area should take health economics into consideration when designing a trial and there is a clear need for health economic evidence and models.
Introduction
Stroke is the third cause of death worldwide and the second cause of disability-adjusted life years in high-income countries [1] . This condition poses a growing global health problem with major individual and societal impact [2] . In the first 5 years after their stroke, about a quarter of patients will suffer from a recurrent stroke [3] and about a fifth of patients will have a myocardial infarction or vascular death [4] . Internationally accepted guidelines provide evidence-based treatment targets to optimize secondary prevention after stroke [5] . These guidelines describe interventions like for example blood pressure control or dietary advice, but do not provide any guidance on how these interventions should be managed and implemented. Patients' adherence to key lifestyle modifications and compliance with pharmacological therapy is poor in current routine practice, with reported compliance rates of about 50% [6] . Digital health interventions (DHIs) that allow for remote interactions between a patient and a caregiver, like web-based interventions or the remote transmission of vital parameters, but mainly comprised of telephone interventions, have shown a mean difference of 6.14 blood pressure-lowering effects in stroke survivors [7] . In the broader field of cardiovascular diseases, DHIs have significantly reduced cardiovascular disease outcomes (relative risk, 0.61) and improved 10-year risk percentages [8] . Even though potential benefits have been shown, implementation of these new solutions in clinical practice has been limited. Most reviews to date have focused on clinical efficacy [7, 8] and lack a thorough search strategy for health economic information. Mapping the costs and cost-effectiveness of DHIs has been identified as a crucial aspect of the evaluation and rollout of DHIs [9] . We searched studies including a health economic analysis of DHIs for secondary prevention in stroke patients.
Methods
We performed and report on a systematic review according to the PRISMA guidelines [10] . A review protocol was drafted prior to the review and is available upon request.
Criteria for Considering Studies for Review Types of Studies
In order to find all available evidence, all study types were accepted.
Types of Participants
We selected only studies that report on stroke patients, aged 18 years or older. All stroke types were accepted including but not limited to: ischemic strokes, hemorrhagic strokes, and transient ischemic attacks.
Types of Interventions
Studies that included DHIs [8] , focused on secondary stroke prevention, were selected for this review. In this study, DHIs were defined as all interventions where digital communication between a patient and a caregiver is leveraged to support patient adherence to lifestyle guidelines to prevent stroke recurrence [5] . Adherence support to at least one lifestyle change or medication advice mentioned in the guidelines was enough for inclusion: (1) blood pressure reduction, (2) cholesterol lowering with a statin, (3) routine use of an antiplatelet agent unless anticoagulants are more appropriate, (4) smoking cessation, (5) reduction of alcohol consumption to 2 drinks per day for men and 1 drink per day for nonpregnant women, (6) for patients who are capable of engaging in physical activities: 3-4 sessions of aerobic exercise per week during 40 min at moderate to vigorous intensity, (7) dietary advice on low intake of saturated fat and salt but plenty of fish, poultry, olive oil, nuts, whole grains, fruit and vegetables, (8) weight reduction in obese individuals, (9) adequate glycemic control in patients with diabetes, and (10) compliance to prescribed medication. Holter monitoring and other long-term monitoring solely for the purpose of further diagnosis were excluded from this review.
Types of Outcome Measures
In order to find all available evidence, all health economic outcome measures were accepted and extracted for analysis and discussion. This includes -but is not limited to -costbenefit analysis (monetary terms), cost-utility analysis (quality adjusted life years) and costeffectiveness analysis (life years saved, or improvement in functional status).
Search Methods and Databases
We performed searches on PubMed, Web of Science, Cochrane, and the National Institute for Health Research Economic Evaluation Database (NHS EED). Only English language papers were included in the search. Studies published before 1990 were not included in the search, because we focused on modern applications that can be used in current clinical practice. Only papers published in peer-reviewed journals were considered. Papers could be published on-line ahead of print.
Search Strategy
We combined the terms "Stroke OR Cardiovascular," "Secondary prevention," "Digital health interventions," and "Costs" in one search string using the AND operator. We used both Mesh terms (PubMed) and free words to maximize output. The search strings were adapted accordingly for each database and are available in supplementary files 1 and 2 (for all online suppl. material, see www.karger.com/doi/10.1159/000496107).
Searching Other Resources
The reference list of all relevant papers and reviews found was screened for additional papers.
Data Collection and Analysis
A first screening was performed by 3 independent screening reviewers based on title and abstract of all articles found by the database searches (after removal of duplicates). One reviewer (A.V.E.) screened all articles and each of the other 2 reviewers screened half the articles (S.S. and K.P.). In case of conflicting decisions, the cases were resolved in a discussion between all 3 reviewers. The remaining articles were screened based on the full texts following the same methodology.
Rayyan [11] was used for gathering all papers found by the searches, removing duplicates and for performing blinded assessment.
Because only health economic outcome parameters were considered, a lot of heterogeneity in the reported results were expected. A meta-analysis on the extracted evidence would be suboptimal and therefore all data was presented, analyzed and discussed descriptively. 
Results
The search performed on April 20, 2017 yielded 163 records of which 26 duplicates were removed (Fig. 1) . After abstract screening, 20 articles were retained for full-text analysis ( Table 1) . Eight articles were excluded mainly, but not exclusively, because they did not report on health economic outcome parameters [12] [13] [14] [15] [16] [17] [18] [19] . Three articles were excluded because the intervention was not a DHI aimed at secondary stroke prevention [20] [21] [22] , 7 articles were excluded because they were reviews after thorough screening of the reference list [15, 23-28], 1 article because it was a study protocol [29] , and another article because the stroke patients were not the target population [30] . Zero papers were withheld for inclusion in this review.
Discussion
We report the first health economic systematic review for DHIs aimed at secondary stroke prevention. Despite the growing field of secondary (stroke) prevention, no studies exist on the health economic aspects of DHIs in contemporary literature. Consequently, no studies met the inclusion criteria for our review.
Although we set broad inclusion criteria -all study designs and all possible health economic outcome parameters were eligible -we still might have missed some studies. We only looked for English literature and did not include articles published before 1990. But given the absence of any evidence found by our systematic search, it seems reasonable to assume that any other studies found would be too limited to be able to draw any conclusions on the cost-effectiveness of DHIs for secondary stroke prevention.
We found some evidence on the cost-effectiveness of monitoring solutions for the detection of atrial fibrillation [20, 22, 32] . Since they do not specifically target secondary stroke prevention, they were excluded from this review. Future designs for or models of DHIs for secondary stroke prevention could be taken into account or integrated with solutions for the detection of atrial fibrillation.
Because secondary prevention in stroke patients also entails secondary cardiovascular prevention, we included "cardiovascular" in our search term, in order to limit the chances of missing relevant studies. One paper withheld for full-text analysis provided some insights on health economic aspects of secondary cardiovascular prevention in general. The trial reports a return on investment of 2.13 for an internet-based case management system for secondary A Cochrane review from 2013 on nonpharmacological interventions for secondary stroke prevention identified 5 ongoing studies [35] , showing increasing interest in the field. When designing future trials on DHIs for secondary prevention in stroke patients it will be important to take health economic aspects into account. Most secondary prevention efficacy trials use surrogate endpoints such as adherence to one or more key parameters, like increased physical activity [36, 37] . Ideally trials would also use stronger endpoints, for instance prevalence of (re-)hospitalizations or cardiovascular events (including stroke). These clinical endpoints are more adequate for translation into health economic endpoints (e.g., quality-adjusted life years gained or lost). Obviously, there is also a lack of insights into the costs of organization of these interventions and potential associated savings compared to standard care. Therefore, we advise more transparent reporting on implementation and real-life costs and to collect data on resource use by patients. An important aspect, which can greatly influence the costeffectiveness of DHIs are the usage and dropout rates. It has been shown that older patients have more trouble to adhere to digital health solutions for support of lifestyle changes [38] and given the advanced average age of stroke patients this might have a negative impact on the cost-effectiveness of DHIs for stroke patients. On the other hand, some evidence suggests that elderly people are well suited to be supported by DHIs for lifestyle changes [39] . Another potential health economic benefit with these types of interventions is the capability to virtually bring the patient in contact with the treating team, without the need for expensive transportation. In the situation that digital interventions would be provided on top of faceto-face visits, the intervention could entail an extra cost. On the other hand, if face-to-face visits can be fully replaced by digital interventions, then this will most likely result in cost savings. Cost transfers from health care systems to patients might be a negative externality -when patients need to install expensive ICT infrastructure or pay for larger mobile data plans. Implementation and cost-effectiveness of DHIs for secondary stroke prevention will also depend on the presence of a legal framework for DHIs, such as reimbursement and liability regulation. With current pursued savings in health care, the potential for reorganization of patient-centered care by the use of DHIs is huge. In order to improve the evaluation of DHIs, there is a need to consider sustainability and cost-effectiveness from the start of their conception and implementation [9] . Our review clearly indicates that this is lacking in the current development and research efforts. Therefore, it is mandatory that more care is given to health economic aspects in future research efforts in order to effectively drive the transformation of health care forward.
Conclusions
There is a lack of evidence on health economic data on DHIs for secondary stroke prevention. Even taking into account very broad inclusion criteria in terms of study design, no studies were included, and no models were found. Future research in this area should take health economics into consideration when designing a trial, and there is a clear need for health economic evidence and models.
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